Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter
NCT02035046 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250
Last updated 2017-01-16
Summary
Gitelman syndrome is a salt wasting tubulopathy caused by mutations in the SLC12A3 gene coding for the thiazide sensitive sodium chloride cotransporter. This disease mimics the chronic treatment with thiazide diuretics and is characterized by renal hypokalemia, low to normal blood pressure, hypocalciuria and hypomagnesemia. The purpose of this study is to determine whether the heterozygous carriers present the metabolic risks and/or the benefits of this disease.
Conditions
- Heterozygous Carriers of Gitelman Syndrome
Interventions
- PROCEDURE
-
Samplings of blood
- PROCEDURE
-
Sampling of urine
- PROCEDURE
-
Measure of the blood pressure
- PROCEDURE
-
glycemia test
Sponsors & Collaborators
-
Ministry of Health, France
collaborator OTHER_GOV -
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Rosa Vargas-Poussou, MD, PhD · Departement of Genetics. Assistance Publique Hôpitaux de Paris,Hôpital Européen Georges Pompidou.
-
Anne Blanchard, MD, PhD · Clinical Research Center. Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou. Paris, France
-
Marie Essig, MD, PhD · Departement of Nephrology. Centre Hospitalier Universitaire. Limoges, France
-
Jean Philippe Haymann, MD, PhD · Department of Functional Investigations. Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France
-
Ivan Tack, MD, PhD · Department of Functional Investigations. Centre Hospitalier Universitaire, Hôpital de Rangueil. Toulouse, France
-
Laurence DUBOURG, MD, PhD · Department of Functional Investigations. Hospices Civils de Lyon, Hôpital Edouard Herriot. Lyon, France
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-12-31
- Primary Completion
- 2016-09-30
- Completion
- 2016-09-30
Countries
- France
Study Locations
More Related Trials
-
Genetic Predisposition to High Blood Pressure
NCT07181213 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Increased Salt Sensitivity of Ambulatory Blood Pressure in Women With a History of Severe Preeclampsia
NCT01874990 ·Status: COMPLETED ·Phase: NA
-
Physiopathology of Sodium Retention in Acromegaly
NCT00531908 ·Status: COMPLETED ·Phase: NA
-
Study on Blood Pressure Variability and Frailty in the Older People
NCT06868069 ·Status: RECRUITING
-
Genetic of Response to Acute Saline Load Test in Hypertension (Naload)
NCT04625569 ·Status: RECRUITING
-
Mortality Outcome of Controlled Hypertension
NCT07187596 ·Status: ACTIVE_NOT_RECRUITING
-
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs
NCT03560804 ·Status: COMPLETED ·Phase: NA
-
Chymase Angiotensin-(1-12) Axis In Hypertensive Disease
NCT05644769 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of Reducing Antihypertensive Treatment on Mortality in Frail Subjects With Low Systolic Blood Pressure (SBP).
NCT03453268 ·Status: COMPLETED ·Phase: NA
-
Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
NCT01009944 ·Status: WITHDRAWN ·Phase: NA
-
Longitudinal Follow-up Study in Two Chinese Hypertension Cohorts
NCT04471389 ·Status: UNKNOWN
-
Genetic Epidemiology of Blood Pressure Intervention
NCT00079690 ·Status: COMPLETED
-
Institutional Registry of Hyponatremia
NCT01370473 ·Status: COMPLETED
-
Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
NCT00004354 ·Status: COMPLETED
-
Blood Pressure and Diurnal Variation in Sodium, Potassium, and Water Excretion
NCT00005204 ·Status: COMPLETED
-
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
NCT00380289 ·Status: UNKNOWN ·Phase: NA
-
Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension
NCT02524873 ·Status: COMPLETED
-
Renal Sympathetic Denervation in Mild Refractory Hypertension
NCT01656096 ·Status: COMPLETED ·Phase: PHASE4
-
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients
NCT01074918 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Genetic Determinant of Blood Pressure Sensitivity to Salt Intake
NCT01706887 ·Status: TERMINATED ·Phase: NA
-
Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency
NCT05211609 ·Status: UNKNOWN ·Phase: NA
-
Feasibility Study of the Intensive Systolic Blood Pressure Control
NCT02817503 ·Status: UNKNOWN ·Phase: PHASE4
-
Potassium and Sodium to Control Blood Pressure in Hypertensives
NCT00000509 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Systemic Microvascular Reactivity in Patients With Resistant Hypertension
NCT05464849 ·Status: COMPLETED
-
Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
NCT00353652 ·Status: COMPLETED ·Phase: PHASE4